Please Wait
Applying Filters...
Drugs in Development
Cambridge Biomedical Inc
Comparative Biosciences, Inc
QUINTA-ANALYTICA s.r.o
CZECH REPUBLIC
UNITED STATES
- Service Details
Specialized software is used for pharmacokinetic and statistical evaluation of study results: SAS® (SAS Institute Inc.,www.sas.com); WinNonlin® Professional (Pharsight Corporation, www.pharsight.com)
- Directory Listing
Pharma Service: Analytical
Category: BioAnalytical ServicesSub Category: Calculation and Modeling of Pharmacokinetic Parameters
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
- Service Details
CBI provides a range of pharmacology and pharmacokinetics capabilities across a spectrum of indications that ensure reliable results in the drug discovery and translation process.
- Directory Listing
Pharma Service: Analytical
Category: BioAnalytical ServicesSub Category: Calculation and Modeling of Pharmacokinetic Parameters
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
- Service Details
CBI offers a variety of preclinical ophthalmic pharmacokinetic, pharmacodynamic and biodistribution study capabilities. Our assessment and analysis modalities are fine-tuned to meet the specific requirements demanded in each targeted area of ophthalmologic pharmacokinetic investigation.
- Directory Listing
Pharma Service: Analytical
Category: BioAnalytical ServicesSub Category: Calculation and Modeling of Pharmacokinetic Parameters
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
- Service Details
Cambridge Biomedical utilizes selective and sensitive immunoassays such as ELISA, MSD and Luminex to implement your PK studies. High performance liquid chromatography, various ligand-binding assays (LBA), cell based assays, and biomarker detection methods to assess pharmacodynamic profiles.
- Directory Listing
Pharma Service: Analytical
Category: BioAnalytical ServicesSub Category: Calculation and Modeling of Pharmacokinetic Parameters
Generic physiologically-based models of pharmacokinetics were evaluated for early drug discovery. Plasma profiles after intravenous and oral dosing were simulated in rat for 68 compounds from six chemical classes. Input data consisted of structure based predictions of lipophilicity, ionization, and protein binding plus intrinsic clearance measured in rat hepatocytes, single measured values of aqueous solubility, and artificial membrane permeability. LogP of compounds was high with a mean of 3.9 while free fraction in plasma (mean 9%) and solubility (mean 37 µg/mL) were low. Predicted and observed clearance and volume showed mean fold-error and R2 of 1.8, 0.56, and 1.9, 0.25 respectively. Predicted bioavailability showed strong bias to under prediction correlated to very low aqueous solubility and a theoretical correction for bile salt solubilization in vivo brought some improvement in average prediction error (to 31%). Overall, this evaluation shows that generic simulation may be applicable for typical drug-like compounds to predict differences in pharmacokinetic parameters of more than twofold based upon minimal measured input data. However verification of the simulations with in vivo data for a few compounds of each compound class is recommended since recent discovery compounds may have properties beyond the scope of the current generic models.
ABOUT THE PAGE
COLLAPSE
PharmaCompass >>
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
Link to Supplier Content
